Latest Conference Articles

Hermine Brunner, MD, MSc, MBA: Secukinumab Treatment in Patients with Juvenile Arthritis

November 11th 2021

American College of Rheumatology Convergence (ACR)

Hermine Brunner, MD, MSc, MBA, discusses secukinumab treatment in patients with enthesitis-related arthritis and juvenile psoriatic arthritis.

Statin Initiation Increases Diabetes Risk in Patients With Rheumatoid Arthritis

November 11th 2021

American College of Rheumatology Convergence (ACR)

While statin initiation was associated with reducing the risk of cardiovascular disease, it may increase in the risk of developing diabetes in patients with rheumatoid arthritis.

Reduced mRNA COVID-19 Vaccine Response in Patients With Rheumatic Disease

November 9th 2021

American College of Rheumatology Convergence (ACR)

Investigators observed stark contrasts in COVID-19 mRNA vaccination response among inflammatory rheumatic disease patients and the general population.

Kyriakos A. Kirou, MD, DSc, FACP: COVID-19 Vaccine Antibody Responses in Patients Treated With B-Cell Agents

November 8th 2021

American College of Rheumatology Convergence (ACR)

Kyriakos A. Kirou, MD, DSc, FACP, explains the key findings of his upcoming ACR presentation, “COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine.”

Kazuki Yoshida, ScD: Gout Treatment Strategies Regarding Cardiovascular Outcomes

November 5th 2021

American College of Rheumatology Convergence (ACR)

Kazuki Yoshida, MD, MPH, ScD, discusses his ACR presentation entitled, “Comparative Safety of Gout "Treat-to-target" and "Usual Care" Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach.”

Lower COVID-19 Immune Response Rate in Patients With Rheumatic Disease

November 5th 2021

American College of Rheumatology Convergence (ACR)

While approximately 80% of patients with rheumatic disease showed humoral immune response rates following the second dose of the COVID-19 vaccine, these numbers were significantly lower than controls.

Laure Gossec, MD, PhD: The Link Between Patient-Reported Outcomes and Disease Activity

November 4th 2021

American College of Rheumatology Convergence (ACR)

Laure Gossec, MD, PhD discusses the association between improvements in patient-reported outcomes and disease activity in patients with psoriatic arthritis.

Patients With Gout at Increased Risk for Lower Extremity Amputation

November 4th 2021

American College of Rheumatology Convergence (ACR)

Investigators analyzed comorbidities, such as diabetes, which has been historically associated with gout, to determine what role, if any, they played in increasing the risk of lower extremity amputation.

Vibeke Strand, MD: Assessing Correlations of Patient-Reported Outcomes in Rheumatoid Arthritis

November 4th 2021

American College of Rheumatology Convergence (ACR)

Vibeke Strand, MD, explores her ACR presentation, “Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib.”

Niti Goel, MD: Depletion of KLRG1+ T Cells in Clinical Trial of ABC008 in Inclusion Body Myositis

November 4th 2021

American College of Rheumatology Convergence (ACR)

Niti Goel, MD, discusses her ACR Convergence presentation entitled, “Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM).”